⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 1, 2024Journal of the American Academy of DermatologyOpen Access

49730 GUIDE trial (part 3): Following guselkumab withdrawal and a long treatment-free period, disease control is rapidly regained upon re-treatment in psoriasis super-responders

Khusru Asadullah Knut Schäkel Andreas Pinter Peter Weisenseel C. Paul Sven Wegner Friedemann Taut Judita Makuc Nikolas Spindler Sarah Tabori Kilian Eyerich

View Full Paper

Ask AI

Bookmark

Share

Abstract

Background: The ongoing Phase IIIb GUIDE trial assesses the impact of guselkumab withdrawal in super-responder (SRe) patients (PASI=0 at both Weeks [W]20+28), and subsequent response to re-treatment if disease control was not maintained.1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Asadullah et al. (2024) studied this question.

synapsesocial.com/papers/68e59e8eb6db643587538879 https://doi.org/10.1016/j.jaad.2024.07.882

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

14CPS-085 Long-term persistence in psoriasis patients with high response to guselkumab: a real-world retrospective study2024
2Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience2024 · 14 citations
3Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study2025 · 8 citations
4SPECTREM Phase 3b Clinical Trial Results Through Week 16: Guselkumab Efficacy and Safety for the Treatment of Low Body Surface Area, Moderate Psoriasis With High-Impact Site Involvement2025 · 4 citations
5Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World DataObservational Study · 2026